| 摘要 |
A method for detecting at least one direct thrombin inhibitor in a patient sample other than citrate plasma, comprising the step of mixing a sample containing a thrombin inhibitor with a composition containing thrombin under conditions which allow the thrombin to release a detectable substance from a chromogenic substrate and measuring the amount of released detectable substrate. The sample may be a body fluid such as serum or urine. The thrombin inhibitor may be a dabigatran, ximelagatran, argatroban, hirudin or modified hirudin. The chromogenic substrate conjugated to a detectable substrate may be benzyl-isoleucine-glutamine-glycine-arginine-para-nitroaniline hydrochloride, tosyl-glycine-proline-arginine-para-nitroaniline, rhodamine 110 or bis-p-tosyl-L-glycyl-L-prolyl-L-arginine amide. |
